- $6.73bn
- $6.28bn
- $22.29m
Arcellx rises as brokerage Leerink lifts PT
U.S. RESEARCH ROUNDUP-Array Technologies, Autodesk, Nike
Brief: Arcellx Inc Estimated Median Progression Free Survival By Kaplan-Meier Is 28 Months
U.S. RESEARCH ROUNDUP-Biomarin Pharmaceutical, Cisco, Microsoft
U.S. STOCKS ON THE MOVE-Thermo Fisher, Palo Alto, American Eagle Outfitters
U.S. STOCKS ON THE MOVE-Kinnate, Walt Disney, VF Corp
U.S. STOCKS ON THE MOVE-Chemomab, Arcellx, Generac
Arcellx gains on expanded cancer treatments pact with Gilead unit
Brief: Kite And Arcellx Announce Expansion In Strategic Partnership
Brief: Arcellx Announces Oral Presentation for Its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma
U.S. STOCKS ON THE MOVE-Arcellx, U.S. Steel, Copper miners
Arcellx rises as FDA lifts partial clinical hold on cancer therapy study
U.S. STOCKS ON THE MOVE-US Foods, BridgeBio, CureVac
U.S. STOCKS ON THE MOVE-Vera Therapeutics, FedEx, US Foods
U.S. STOCKS ON THE MOVE-Innovative Eyewear, BranchOut Food, Estee Lauder
U.S. STOCKS ON THE MOVE-Cano Health, Arcellx, Dice Therapeutics
Arcellx falls after FDA puts cancer therapy study on hold
U.S. RESEARCH ROUNDUP- Cigna Group, McKesson, Zscaler
Brief: Arcellx Provides First Quarter Financial Results